… therapies, making upfront combination treatment a safe and effective option … Research III, professor of medicine and chief of section of … consensus in diagnosis or treatment that you hope will emerge … believer in the use of Rituxan in the frontline setting, …

… Management. Older cancer drug Rituxan and anti-inflammatory Actemra … treatments as well as heavy investments in experimental obesity drugs … 4 billion francs. Pharmaceutical division sales for the … biotech unit Genentech plans to offer influenza antiviral pill …

… it stands, the lupus treatment market—across several distinct … severe SLE.  Doctors have also used another Roche drug, Rituxan, off- … after Rituxan fell short in a phase 3 trial. Meanwhile … FDA endorsement comes less than a week after the European Medicine …

… . Milliken Department of Medicine of Washington University, … trial, displaying benefit with obinutuzumab (Gazyva) vs rituximab (Rituxan) … cell lymphoma doctors, and your follicular lymphoma…doctors,” he … that may better individualize treatment for patients. An …

… ongoing phase 2 SIDNEY trial (NCT04669171).1 Under this … invites an opportunity for treatment through immunotherapies, the disease … s proprietary OncoMimics™ platform. Drugs that use this platform … and/or rituximab (Rituxan) in patients with indolent NHL …

… Department of Engineering for Innovative Medicine at the University of … (NCT03567876) of bendamustine plus rituximab (Rituxan; BR) plus intermediate-dose cytarabine … MCL. The trial’s inclusion criteria required histologically confirmed, treatment-naive MCL …

… lupus erythematosus (SLE) trial FPI achieved, enrollment ongoing … Hope In Reducing Lifelong Treatment Burden For Autoimmune … (NASDAQ:BIIB) partnered Rituxan (rituximab) and recent approvals … an Investigational New Drug (IND) or Clinical Trial Application (CTA …

… an assistant professor of Medicine (Hematology) at Yale … therapeutic combinations across multiple treatment lines and settings, … cell lymphomas, stating that multiple trials are ongoing in … Rituxan], which is being studied. In addition, we have a trial …

… Because crossover can “confound treatment effect estimates…, its use … (Rituxan). The study was designed as a confirmatory trial to … it seems possible that the FDA would deny full approval. … in trials, delayed read-outs on clinical trial results, delayed drug …

… full professor, Department of Medicine, University Hospital LMU Munich, … ) plus bendamustine plus rituximab (Rituxan; BR) in previously untreated … the FDA approved acalabrutinib plus BR for the treatment … Dreyling noted that the trial faced the unique challenge …